Brief: Finch Therapeutics Announces Start Of Enrollment In PRISM4 Phase 3 Trial
09/11/2021 23:36
Nov 9 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM
PRISM-EXT PHASE 2 TRIAL OF CP101 FOR PREVENTION OF RECURRENT C.
DIFFICILE INFECTION
* FINCH THERAPEUTICS GROUP - NEW DATA FROM 132-PARTICIPANT
PRISM-EXT PHASE 2 OPEN-LABEL TRIAL SHOW 80.3% SUSTAINED CLINICAL
CURE RATE THROUGH 8 WEEKS
* FINCH THERAPEUTICS GROUP INC - AGGREGATED 88.2% SUSTAINED
CLINICAL CURE RATE SHOWN THROUGH 8 WEEKS FOLLOWING LAST DOSE IN
POST-HOC ANALYSIS
* FINCH THERAPEUTICS GROUP INC - ANNOUNCES START OF
ENROLLMENT IN
PRISM4 PHASE 3 TRIAL
* FINCH THERAPEUTICS GROUP INC - SIMILAR CLINICAL CURE RATE
MAINTAINED THROUGH 24 WEEKS AND A SAFETY PROFILE CONSISTENT WITH
PREVIOUSLY REPORTED DATA
Source text for Eikon: ID:nGNX17lwrq
Further company coverage: FNCH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp